** Brokerage TD Cowen downgrades drugmaker Merck's MRK.N shares to "hold" from "buy" on weak forecast and a "lack of clarity" regarding shipment of its HPV vaccine Gardasil in China
** Last week, MRK forecast total revenues below Wall Street estimates and said it would not ship Gardasil in China until at least the middle of the year
** Lowers PT to $100 from $121 on reduced profit and sales estimates for each year through 2030
** Brokerage says MRK's business development effort seems to have lost momentum ahead of blockbuster cancer therapy Keytruda losing key patents in 2028
** Beyond Keytruda, MRK's growth story "has not improved convincingly" despite a promising pipeline of experimental treatments, brokerage says
** MRK's price to earnings ratio (P/E), a common benchmark for valuing stocks, will trough in 2026 - two years before Keytruda loses exclusivity, TD Cowen says
** Stock has fallen 24% since late July when it first disclosed Gardasil troubles
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.